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RESULTS: The cost model generated an estimated retail price of
€55 or €113 for the neck brace depending on assumptions. The
estimated retail price for the neck brace was lower than the
reimbursement tariff of €194 and the actual retail price of €241.
With respect to the knee brace, the estimated retail price of €331
or €523 was inferior to the tariff of €580 and the actual retail
price of €948. CONCLUSION: Actual retail prices and reim-
bursement tariffs for two selected neck and knee braces substan-
tially exceeded retail prices based on estimated production and
distribution costs. Therefore, there seems to be scope for reduc-
ing reimbursement tariffs and containing public expenditure on
orthotic braces.
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OBJECTIVE: The Israeli National Health Insurance Law stipu-
lates aNational List ofHealth Services (NLHS)which all residents
are entitled from their HMOs. This list has been updated annually
for almost a decade using a structured review and decision-making
process. Although the Israeli explicit priority-setting experience is
unique and may be considered groundbreaking, its fairness and
legitimacy have not been assessed. To assess the priority-setting
process for compliance with the four conditions of accountability
for reasonableness outlined by Daniels and Sabin (relevance,
publicity, appeals, and enforcement), andwith the four steps of the
trans-disciplinary model for priority setting in health care (rea-
sonableness, transparency, responsiveness, and accountability).
METHODS: We used such data as public documents, audit
reports, literature review, the mass media, observations from the
meetings of the Public Adivosry Committee responsible for rec-
ommending new technologies for th NLHS, and interviews with
the committeemembers.RESULTS:The Israeili process for updat-
ing the NLHS does not fulﬁll the appeals and enforcement
conditions, and only partially follows the publicity and relevance
conditions, outlinesd in the accountabilty for reasonableness and
transparency framework. Only the reasonableness and transpar-
ency steps of the trans-disciplinary model are partially fulﬁlled,
but the priority setting process lacks responsiveness and account-
ability. CONCLUSION: The fairness and legitimacy of the
priority-setting mechanism have not been established. The main
obstacles for achieving these goals may relate to the large number
of technologies assessed each year within a short time frame (500
technologies assessed in 2007), the lack of personnel engaged in
health technology assessment and the desire for early adoption of
new technologies. Changes in the priority-setting process should
be made in order to increase its acceptability among the different
stakeholders.
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OBJECTIVE: Stakeholder involvement in health technology
assessment (HTA) is of growing importance, as their participa-
tion in and support of economic evaluation is generally con-
sidered to improve the assessment process and subsequent
implementation. Consequently, in early 2007, the Health Select
Committee of the UK House of Commons initiated a public
inquiry into the National Institute of Health and Clinical Excel-
lence (NICE), calling for comments from a variety of stake-
holders. This study aimed to examine stakeholder perspectives
on several topics, including public conﬁdence in NICE; appro-
priateness of economic evaluation methods; and, effectiveness of
guidance implementation. METHODS: All stakeholder submis-
sions (n = 92) were systematically reviewed and key themes were
identiﬁed across three principal categories: 1) organisation and
process; 2) methods; and 3) decision-making and implementa-
tion. RESULTS: Stakeholders identiﬁed a number of overarching
issues regarding NICE and economic evaluation, more broadly.
Firstly, despite its “arms-length” organisational structure, NICE
is perceived to lack independence. Secondly, stakeholders con-
tented that its methods assume an overly narrow perspective,
especially regarding the use of RCTs, QALYs, and measures of
costs and beneﬁts. Thirdly, commentators asserted that manufac-
turers, clinical experts, and patients should play a greater role in
HTA processes. Fourthly, the time taken to issue guidance was
considered an important limitation, especially given evidence
that local decision-makers delay the introduction of new treat-
ments pending NICE’s decision(s). Other key concerns included
inconsistent local implementation of guidance and the overall
transparency of NICE operations. CONCLUSION: Most stake-
holders support the overall role of NICE in the NHS, and
acknowledge that the Institute generally undertakes rigorous
assessments. Nevertheless, many criticisms were put forth by
stakeholders. NICE should continue to capitalise on its strengths,
while pioneering solutions to address existing limitations and
challenges. However, it is unlikely that any national HTA system
will satisfy the needs and expectations of all key parties.
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OBJECTIVE: To evaluate a methodology of managing high cost
patients, called Case Management Program (CMP), within a
private health plan in southern Brazil and show that such
program is cost-effective and the return on investment (ROI) is
positive. METHODS: Using NAGIS(c) model and software for
disease management program, the CMP was implemented in
211 patients (0.9% of the health plan beneﬁciaries). I compared
health plan utilization and costs including CMP costs of one
period of time before the program starts with the same period of
time that the program was in place. RESULTS: After 9 months of
CMP, there were 162 patients. I considered outcomes for these
162 patients. For one Real invested, R$4,78 was saved (One
2008 American Dollar is 1,78 Brazilian Real). The average cost
per enrollee per month reduced 45.9% (R$463,85 to R$250,89)
and 39.4% (R$463,85 to R$280,90) if the program’s costs
(direct and indirect costs) are included as ﬁxed costs. The number
of visits reduced by 11.3% (794 to 704), as well as the labs
exams which reduce 35.7% (420 to 270). Nevertheless, the labs
exams per visit index reduce by 27.5%, where almost 53% of the
visits had at least one exam before starting the program against
38.3% after the same period of time that the program starts. The
number of hospitalizations reduced 34.6%, from 483 to 316.
Thus, the bed-days saved were 554 days at inﬁrmaries and 62
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